Prices are updated after-hours

Health Technology Glass

Harpoon Therapeutics, Inc.

HARP | $23.01 0.07% 6.6M

|

Health Technology

(0.0% 1d) (0.0% 1m) (3608.1% 1y) (0.0% 2d) (0.1% 3d) (0.0% 7d) (122.25% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 389,611,579
http://www.harpoontx.com
Sec Filling | Patents | 61 employees

(US) Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which develops a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTACs) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.

cancer immunotherapy glass t-cell treatment ceiling construction

add to watch list Paper trade email alert is off

IMV Inc.

IMV | $0.8225 -2.74% 45K

|

Health Technology

(0.0% 1d) (0.0% 1m) (22.8% 1y) (-2.5% 2d) (-2.5% 3d) (0.0% 7d) (-76.64% volume)
Earnings Calendar: 2023-05-12
Market Cap: $ 9,632,821
http://www.imv-inc.com
Sec Filling | Patents | n/a employees

IMV, Inc. is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities. Its drug candidate, DPX-Survivac, is a targeted T cell therapy that has completed multiple phases 1 and 1b trials generating results in late-stage ovarian cancer and relapsed/refractory DLBCL (Diffuse Large B Cell Lymphoma) where it has identified a predictive biomarker. The company was founded by Warwick Kimmins and Brian E. Lowe on May 18, 2007 and is headquartered in Dartmouth, Canada.

vaccine covid cancer ovarian cancer immunotherapy infectious disease glass t-cell ceiling

add to watch list Paper trade email alert is off

Bicycle Therapeutics plc

BCYC | $24.515 0.1% 160K

|

Health Technology

(0.0% 1d) (-14.4% 1m) (11.7% 1y) (0.0% 2d) (0.0% 3d) (0.5% 7d) (-39.58% volume)
Earnings Calendar:
Market Cap: $ 522,287,197
http://www.bicycletherapeutics.com
Sec Filling | Patents | 72 employees

(United Kingdom) Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

glass

add to watch list Paper trade email alert is off

Bausch Health Companies Inc.

BHC | $8.63 0.35% 1.5M

|

Health Technology

(0.0% 1d) (-8.9% 1m) (13.7% 1y) (0.0% 2d) (0.0% 3d) (1.3% 7d) (-8.18% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 3,115,341,491
http://www.bauschhealth.com
Sec Filling | Patents | 21700 employees

Bausch Health Cos., Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Branded Rx segment comprises of pharmaceutical products related to the Salix product portfolio; dermatological product portfolio; branded pharmaceutical products, branded generic pharmaceutical products; over-the-counter products; medical device products; Bausch + Lomb products sold in Canada; and the oncology, dentistry, and health products for women. The Salix Segment consists of sales in the U.S. of GI Products, The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

glass urea aesthetic women brands neurological

add to watch list Paper trade email alert is off

Alnylam Pharmaceuticals, Inc.

ALNY | News | $145.89 0.5% 170K

|

Health Technology

(0.0% 1d) (-1.9% 1m) (-28.4% 1y) (0.0% 2d) (0.0% 3d) (-1.7% 7d) (13.19% volume)
Earnings Calendar: 2024-02-15
Market Cap: $ 18,374,231,741
http://www.alnylam.com
Sec Filling | Patents | 1323 employees

(US) Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

glass genetic msa treatment

Drugs

GIVLAARI (givosiran sodium)
Onpattro (patisiran)
OXLUMO (lumasiran)

add to watch list Paper trade email alert is off

Tenax Therapeutics, Inc.

TENX | $3.62 -1.63% 9K

|

Health Technology

(0.0% 1d) (-4.4% 1m) (929.1% 1y) (0.0% 2d) (2.5% 3d) (2.1% 7d) (-16.43% volume)
Earnings Calendar: 2022-11-14
Market Cap: $ 6,407,400
http://www.tenaxthera.com
Sec Filling | Patents | 9 employees

(US) Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The company has a world-class scientific advisory team, including recognized global experts in pulmonary hypertension. The company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding its Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). The company was founded on May 26, 1967 and is headquartered in Morrisville, NC.

cardiovascular heart glass hypertension pulmonary hypertension clinical trials treatment

add to watch list Paper trade email alert is off

Genprex, Inc.

GNPX | $2.2194 22K

|

Health Technology

(0.0% 1d) (-25.8% 1m) (100.9% 1y) (0.0% 2d) (0.0% 3d) (-6.0% 7d) (1.87% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 4,240,033
http://www.genprex.com
Sec Filling | Patents | 8 employees

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company's lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca's Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. The company was founded by J. Rodney Varner in April 2009 and is headquartered in Austin, TX.

cancer lung cancer gene therapies diabetes diabetic glass food t-cell lungs treatment msa ceiling

add to watch list Paper trade email alert is off

Aileron Therapeutics, Inc.

ALRN | $4.82 -3.6% 69K

|

Health Technology

(0.0% 1d) (-2.7% 1m) (252.0% 1y) (0.0% 2d) (0.0% 3d) (-9.8% 7d) (1178.57% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 81,807,508
http://www.aileronrx.com
Sec Filling | Patents | 13 employees

Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.

cancer glass t-cell nash treatment ceiling

add to watch list Paper trade email alert is off

Shattuck Labs, Inc.

STTK | $9.92 -2.07% 220K

|

Health Technology

(0.0% 1d) (5.8% 1m) (257.9% 1y) (0.0% 2d) (0.0% 3d) (10.2% 7d) (128.71% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 470,949,847
http://www.shattucklabs.com
Sec Filling | Patents | 105 employees

Shattuck Labs, Inc. engages in the research and development of Agonist Redirected Checkpoint (ARC) platform. It develops a novel class of biologic medicines, capable of multifunctional activity, with potential applications in oncology and autoimmune diseases. The company was founded by Josiah C. Hornblower and Taylor Schreiber in 2016 and is headquartered in Austin, TX.

autoimmunity glass

add to watch list Paper trade email alert is off

aTyr Pharma, Inc.

LIFE | $1.605 -0.93% 95K

|

Health Technology

(0.0% 1d) (-19.8% 1m) (-5.8% 1y) (0.0% 2d) (1.9% 3d) (-4.7% 7d) (-48.54% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 109,045,050
http://www.atyrpharma.com
Sec Filling | Patents | 44 employees

(US) aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. It operates in a single accounting segment. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

glass diagnostics

add to watch list Paper trade email alert is off

Karyopharm Therapeutics Inc.

KPTI | $1.255 -1.95% 620K

|

Health Technology

(0.0% 1d) (-8.6% 1m) (-66.3% 1y) (0.0% 2d) (-7.2% 3d) (10.8% 7d) (-58.87% volume)
Earnings Calendar: 2024-02-14
Market Cap: $ 144,409,189
http://www.karyopharm.com
Sec Filling | Patents | 347 employees

(US) Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

cancer autoimmunity glass treatment msa nuclear

Drugs

XPOVIO (selinexor)

add to watch list Paper trade email alert is off

Generation Bio Co.

GBIO | $2.79 0.36% 100K

|

Health Technology

(0.0% 1d) (-7.5% 1m) (-32.6% 1y) (0.0% 2d) (0.0% 3d) (-19.5% 7d) (31.32% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 185,471,140
http://www.generationbio.com
Sec Filling | Patents | 85 employees

Generation Bio Co. is a genetic medicines company focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. Its non-viral platform incorporates a proprietary high-capacity DNA construct called closed-ended DNA, or ceDNA; a novel cell-targeted lipid nanoparticle delivery system, or ctLNP; and an established, scalable capsid-free manufacturing process. The company was founded by Mark D. Angelino, Jason P. Rhodes, and Robert M. Kotin in 2016 and is headquartered in Cambridge, MA.

gene therapies glass t-cell genetic treatment ceiling construction

add to watch list Paper trade email alert is off

C4 Therapeutics, Inc.

CCCC | $6.56 -5.07% 1.2M

|

Health Technology

(0.0% 1d) (-22.0% 1m) (111.3% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (-10.06% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 450,020,389
http://www.c4therapeutics.com
Sec Filling | Patents | 99 employees

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.

glass t-cell ceiling

add to watch list Paper trade email alert is off

Intellia Therapeutics, Inc.

NTLA | $20.99 -1.55% 560K

|

Health Technology

(0.0% 1d) (-23.3% 1m) (-40.4% 1y) (0.0% 2d) (-0.8% 3d) (-7.0% 7d) (6.36% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 2,024,246,382
http://www.intelliatx.com
Sec Filling | Patents | 270 employees

(US) Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

crispr genomic genome editing glass

add to watch list Paper trade email alert is off

Cue Biopharma, Inc.

CUE | $1.535 -2.85% 120K

|

Health Technology

(0.0% 1d) (-24.5% 1m) (-57.6% 1y) (0.0% 2d) (0.0% 3d) (-6.3% 7d) (19.96% volume)
Earnings Calendar: 2024-03-12
Market Cap: $ 74,667,490
http://www.cuebiopharma.com
Sec Filling | Patents | 47 employees

(US) Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.

cancer autoimmunity glass

add to watch list Paper trade email alert is off

Foghorn Therapeutics Inc.

FHTX | $5.35 -3.26% 92K

|

Health Technology

(0.0% 1d) (-10.9% 1m) (-20.7% 1y) (0.0% 2d) (0.0% 3d) (-20.5% 7d) (56.15% volume)
Earnings Calendar: 2022-11-08
Market Cap: $ 227,727,586
http://www.foghorntx.com
Sec Filling | Patents | 85 employees

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

glass msa

add to watch list Paper trade email alert is off

Intra-Cellular Therapies Inc.

ITCI | News | $71.4 -0.83% 1.3M

|

Health Technology

(0.0% 1d) (10.4% 1m) (22.0% 1y) (0.0% 2d) (-4.8% 3d) (13.1% 7d) (NaN% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 6,912,033,437
http://www.intracellulartherapies.com
Sec Filling | Patents | 330 employees

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.

neurodegenerative schizophrenia glass alzheimer heavy drug nervous system neuropsychiatric molecule drugs neurological msa treatment alzheimer’s

add to watch list Paper trade email alert is off

Precigen, Inc.

PGEN | $1.29 -2.27% 480K

|

Health Technology

(0.0% 1d) (-9.0% 1m) (12.9% 1y) (0.0% 2d) (0.0% 3d) (-6.4% 7d) (-4.32% volume)
Earnings Calendar: 2023-11-08
Market Cap: $ 321,105,634
http://www.precigen.com
Sec Filling | Patents | 857 employees

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. The firm focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. It operates through the following segments: PGEN Therapeutics, ActoBio, MBP Titan, Trans Ova and All Other. The PGEN Therapeutics segment is advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders and infectious diseases. The ActoBio segment involves in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The MBP Titan segment comprises of Methane Bioconversion Platform, and associated technologies, personnel, and facilities The Trans Ova segment includes provides advanced reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

autoimmunity infectious disease glass food t-cell ceiling

add to watch list Paper trade email alert is off

Dr. Reddy's Laboratories Ltd

RDY | $71.05 0.2% 71K

|

Health Technology

(0.0% 1d) (-2.1% 1m) (19.5% 1y) (0.0% 2d) (0.0% 3d) (0.3% 7d) (-5.04% volume)
Earnings Calendar:
Market Cap: $ 11,856,677,566
http://www.drreddys.com
Sec Filling | Patents | 21650 employees

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

glass pest brands

add to watch list Paper trade email alert is off

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

71%

29%

Top 10 Gainers

AGBA | News | $1.27 217.5% 120M

|

EGOX | $0.0503 39.72% 320M

|

RWOD | $10.52 31.56% 5.9M

|

ZCMD | $1.905 31.38% 30M

|

Commercial Services

MRDB 4 | $0.536 27.65% 2M

|

BSFC | $0.0822 27.64% 75M

|

TPET | $0.4121 25.68% 45M

|

NVFY | $2.65 25.59% 33M

|

Consumer Durables

INDO | $5.1 25.0% 15M

|

Energy Minerals

CHRO | $1.53 24.9% 100K

|

Last 48 Hours Insiders Buying

CLSD | $1.42 7.58% 170K

|

Health Technology

| 14:00
CDZI P 25000 | $2.25 100K

|

| 14:00
ETST P 39000 | $0.068 43K

|

| 13:30
FNLC P 1275 | $22.91 3.38% 13K

|

| 12:30
ADMQ | $0.0532 480K

|

| 10:30
AXR P 2400 | $21.02 -5.19% 3.5K

|

| 21:00
QCRH P 118 | $56.48 1.93% 15K

|

| 18:01
VUZI P 7500 | $1.26 230K

|

Electronic Technology

| 18:00
RMCF | $3.69 3.94% 9.5K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar